| Abstract |
[Abstract] Objective To explore the effect of classical and non-classical antipsychotic drugs on the efficacy, social function and safety of patients with schizophrenia. Methods Eighty patients with schizophrenia from May 2016 to December 2017 in our hospital were selected and divided into group A (n=35) and group B (n=45) according to different treatment plans. Group A was treated with classic antipsychotic drugs, and group B was treated with non-classical antipsychotic drugs. The positive and negative symptoms scale (PANSS), personal and social function scale (PSP), quality of life scale (QOL) scores and adverse drug reaction rates were compared between the two groups at baseline, 1-year follow-up, and 2-year follow-up. Results The scores of negative symptoms, excitement/hostility, anxiety/depression, and cognition in group B were lower than those in group A during 1 year follow-up and 2 years follow-up (P＜0.05); there was no significant difference in positive symptom score between the two groups for 1 year and 2 years (P>0.05); the PSP score in group B was higher than that in group A, and the QOL score was lower than group A during the follow-up for 1 year and 2 years (P<0.05); the incidence of increased prolactin, blood glucose/dyslipidemia, and weight gain in group B was higher than that in group A, and the incidence of drowsiness, tremor, muscle rigidity, akathisia, dry mouth/constipation, and delayed dyskinesia was lower in group A (P<0.05). Conclusion Classic and non-classical antipsychotic drugs have equivalent efficacy in the treatment of patients with schizophrenia, but non-classical drugs have obvious advantages in improving patients negative symptoms, cognitive function, emotional symptoms and social function, and have higher safety.
|